Effervescent paracetamol termalgin — Competitive Intelligence Brief

Effervescent paracetamol termalgin (Effervescent paracetamol termalgin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Analgesic and antipyretic. Area: Pain management.

marketed Analgesic and antipyretic Cyclooxygenase (COX) Pain management Small molecule

Target snapshot

Effervescent paracetamol termalgin (Effervescent paracetamol termalgin) — Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina. Paracetamol inhibits prostaglandin synthesis by blocking cyclooxygenase enzymes, reducing pain and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Effervescent paracetamol termalgin TARGET	Effervescent paracetamol termalgin	Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina	marketed	Analgesic and antipyretic	Cyclooxygenase (COX)
Tylenol (Acetaminophen)	Tylenol (Acetaminophen)	University of Nebraska	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Panadol®	Panadol®	Sinew Pharma Inc.	marketed	Analgesic and antipyretic (non-NSAID)	Cyclooxygenase (COX), primarily in central nervous system
Acetaminophen/APAP	Acetaminophen/APAP	John van den Anker	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Postoperative pain management with acetaminophen	Postoperative pain management with acetaminophen	University Hospital Sestre Milosrdnice	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Acetaminophen Injection	Acetaminophen Injection	Mount Sinai Hospital, Canada	marketed	Analgesic and antipyretic	Cyclooxygenase (COX)
Non- effervescent Paracetamol kern	Non- effervescent Paracetamol kern	Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina	marketed	Analgesic and antipyretic	Cyclooxygenase (COX-1, COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Analgesic and antipyretic class)

1. Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina · 2 drugs in this class
2. Mallinckrodt · 2 drugs in this class
3. The University of Texas Health Science Center, Houston · 2 drugs in this class
4. Hellenic Society of Hematology · 1 drug in this class
5. John van den Anker · 1 drug in this class
6. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 drug in this class
7. Maoxiang Group Jilin Pharmaceutical Co., Ltd. · 1 drug in this class
8. Merck Sharp & Dohme LLC · 1 drug in this class
9. Mount Sinai Hospital, Canada · 1 drug in this class
10. Nantes University Hospital · 1 drug in this class